Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.

Olga Gajic-VeljanoskiChunmei LiAlexis K SchainkJennifer GuoNadine ShehataGeorge S CharamesBarbra de VrijerGwen ClarkePetros PechlivanoglouNanette OkunRita KandelJoseph DooleyCaroline HigginsVivian NgNancy Sikich

Published in: Transfusion (2022)

Noninvasive fetal RhD genotyping saves resources and represents good value for the management of alloimmunized pregnancies. If the cost of genotyping is substantially decreased, the targeted intervention can become a viable option for nonalloimmunized pregnancies.

Keyphrases

preterm birth
genome wide
high throughput
gestational age
pregnancy outcomes
genetic diversity
randomized controlled trial
dna methylation
cancer therapy
gene expression
drug delivery